SCHEMBL20965398

SCHEMBL20965398

Cc1noc(CSc2ccccc2C(=O)N2CCN(c3ccc(C(F)(F)F)cn3)CC2)n1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 10/20 0.57
SMN1; SMN2 Q16637 9/20 0.57
HTT P42858 6/20 0.57
KDM4E B2RXH2 5/20 0.57
ALDH1A1 P00352 7/20 0.56
MAPT P10636 3/20 0.56
POLB P06746 1/20 0.56
THRB P10828 1/20 0.56
GLA P06280 1/20 0.51
MEN1 O00255 2/20 0.51
KMT2A Q03164 2/20 0.51
TSHR P16473 2/20 0.51
CYP1A2 P05177 1/20 0.51
CYP2C9 P11712 1/20 0.51
CYP2C19 P33261 1/20 0.51
MAPK1 P28482 1/20 0.51
L3MBTL1 Q9Y468 1/20 0.50
HPGD P15428 1/20 0.49
GAA P10253 1/20 0.47
NAMPT P43490 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20964555 0.87 ALDH1A1 (0.49) LMNASMN1; SMN2HTTKDM4EALDH1A1
SCHEMBL20965423 0.87 LMNA (0.57) LMNASMN1; SMN2HTTKDM4EALDH1A1
SCHEMBL20965401 0.85 LMNA (0.68) LMNASMN1; SMN2HTTKDM4EALDH1A1
SCHEMBL20964545 0.85 LMNA (0.59) LMNASMN1; SMN2HTTKDM4EALDH1A1
SCHEMBL20965374 0.85 MAPT (0.52) LMNASMN1; SMN2KDM4EALDH1A1MAPT
SCHEMBL20965291 0.84 L3MBTL1 (0.55) LMNASMN1; SMN2HTTALDH1A1MAPT
SCHEMBL20964633 0.80 LMNA (0.57) LMNASMN1; SMN2HTTKDM4EALDH1A1
SCHEMBL20964626 0.80 LMNA (0.57) LMNASMN1; SMN2HTTKDM4EALDH1A1
SCHEMBL20964937 0.77 LMNA (0.58) LMNASMN1; SMN2HTTALDH1A1MAPT
SCHEMBL20965436 0.77 L3MBTL1 (0.63) LMNASMN1; SMN2HTTKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10851096-B2 Aryl and heteroaryl amides for use as anti-proliferative, anti-thrombotic, and anti-viral agents RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2020-12-01 US disclosed
US-20190127361-A1 Therapeutic Compounds RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2019-05-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190127361-A1 Therapeutic Compounds SDHA, SLC10A1, SERPINC1 LMNA 1413/4885SMN1; SMN2 263/4885HTT 2154/4885
US-10851096-B2 Aryl and heteroaryl amides for use as anti-proliferative, anti-thrombotic, and anti-viral agents SERPINC1, F12, RPL35 LMNA 897/4885SMN1; SMN2 2477/4885HTT 2335/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.